WHO removes TB and malaria drug APIs made by Anuh Pharma from approved list

By Gareth Macdonald

- Last updated on GMT

WHO World Health Organization Headquarters in Geneva, Switzerland (iStock/mseidelch)
WHO World Health Organization Headquarters in Geneva, Switzerland (iStock/mseidelch)

Related tags Pharmacology Pharmaceutical drug

The WHO has removed two APIs supplied by Anuh Pharma from its list of prequalified ingredients and announced plans to inspect the firm’s facility in Boisar, India.

The World Health Organisation​ (WHO) announced the suspension yesterday, explaining that the move follows criticism​ of operations at the site by French regulator ANSM last month and the subsequent withdrawal of its GMP certificate.

The WHO said: “In the absence of current EU GMP certification, an acceptable standard of GMP can no longer be presumed at this [Boisar] facility.

WHOAPI-158 and WHOAPI-234 will be removed from the WHO List of prequalified APIs until such time as WHO PQT can verify that an acceptable level of GMP is present at the manufacturing site​.”

The APIs in question are pyrazinamide, which is used in tuberculosis drugs, and sulfadoxine, which is used in treatments for malaria.

The WHO told drug formulators to stop sourcing either ingredient from Anuh and to analyse any batches they have already purchased.

Anuh Pharma – which confirmed the suspension in a Bombay Stock Exchange (BSE) filing​ – has asked the WHO to re-inspect the facility.

ANSM criticism

Anuh facility processes APIs supplied by other manufacturers and supplies them to pharmaceutical producers.

ANSM inspectors who visited in February observed 24 deficiencies from good manufacturing practices (GMP) standards according to a report published on EudraGMP​ in March.

The major deviation was Anuh’s failure to pass details of its suppliers on to customers to which it sold processed active pharmaceutical ingredients (API).

The ANSM team also reported that azithromycin supplied to Europe labelled as being manufactured by Anuh was actually made by a non-compliant Chinese supplier called Hebei Dongfeng Pharmaceutical.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more